Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/104191
Title: | Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia |
Author: | Brissot, Eolia Labopin, Myriam Beckers, Marielle M. Socié, Gérard Rambaldi, Alessandro Volin, Liisa Finke, Jürgen Lenhoff, Stig Kröger, Nicolaus Ossenkoppele, Gert J. Craddock, Charles F. Yakoub-Agha, Ibrahim Gürman, Günhan Russell, Nigel H. Aljurf, Mahmoud Potter, Michael N. Nagler, Arnon Ottmann, Oliver Cornelissen, Jan J. Esteve Reyner, Jordi Mohty, Mohamad |
Keywords: | Leucèmia limfocítica crònica Cèl·lules mare Inhibidors enzimàtics Chronic lymphocytic leukemia Stem cells Enzyme inhibitors |
Issue Date: | Mar-2015 |
Publisher: | Ferrata Storti Foundation |
Abstract: | This study aimed to determine the impact of tyrosine kinase inhibitors given pre- and post-allogeneic stem cell transplantation on long-term outcome of patients allografted for Philadelphia chromosome-positive acute lymphoblastic leukemia. This retrospective analysis from the EBMT Acute Leukemia Working Party included 473 de novo Philadelphia chromosome-positive acute lymphoblastic leukemia patients in first complete remission who underwent an allogeneic stem cell transplantation using a human leukocyte antigen-identical sibling or human leukocyte antigen-matched unrelated donor between 2000 and 2010. Three hundred and ninety patients received tyrosine kinase inhibitors before transplant, 329 at induction and 274 at consolidation. Kaplan-Meier estimates of leukemia-free survival, overall survival, cumulative incidences of relapse incidence, and non-relapse mortality at five years were 38%, 46%, 36% and 26%, respectively. In multivariate analysis, tyrosine-kinase inhibitors given before allogeneic stem cell transplantation was associated with a better overall survival (HR=0.68; P=0.04) and was associated with lower relapse incidence (HR=0.5; P=0.01). In the post-transplant period, multivariate analysis identified prophylactic tyrosine-kinase inhibitor administration to be a significant factor for improved leukemia-free survival (HR=0.44; P=0.002) and overall survival (HR=0.42; P=0.004), and a lower relapse incidence (HR=0.40; P=0.01). Over the past decade, administration of tyrosine kinase inhibitors before allogeneic stem cell transplantation has significantly improved the long-term allogeneic stem cell transplantation outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Prospective studies will be of great interest to further confirm the potential benefit of the prophylactic use of tyrosine kinase inhibitors in the post-transplant setting. |
Note: | Reproducció del document publicat a: https://doi.org/10.3324/haematol.2014.116954 |
It is part of: | Haematologica, 2015, vol. 100, num. 3, p. 392-399 |
URI: | http://hdl.handle.net/2445/104191 |
Related resource: | https://doi.org/10.3324/haematol.2014.116954 |
ISSN: | 0390-6078 |
Appears in Collections: | Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
663502.pdf | 266.17 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.